7.6.2025
Michal Pazderník
“Timing of renal replacement therapy in ICU patients“
AKI and Acute cardiovascular diseases
Jentzer JC, Bihorac A, Brusca SB, et al. Contemporary Management of Severe Acute Kidney Injury and Refractory Cardiorenal Syndrome: JACC Council Perspectives. J Am Coll Cardiol. 2020 Sep 1;76(9):1084-1101.
Singh S, Kanwar A, Sundaragiri PR, et al. Acute Kidney Injury in Cardiogenic Shock: An Updated Narrative Review. J Cardiovasc Dev Dis. 2021 Jul 28;8(8):88.
Ru SC, Lv SB, Li ZJ. Incidence, mortality, and predictors of acute kidney injury in patients with heart failure: a systematic review. ESC Heart Fail. 2023 Dec;10(6):3237-3249.
Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015 Aug;41(8):1411-23.
Pazdernik M, Ostadal P, Seiner J, et al. Clinical characteristics, management and predictors of mortality: results from national prospective cardiogenic shock registry (CZECH-SHOCK). Eur Heart J Acute Cardiovasc Care. 2025 Feb 28:zuaf034.
Early RRT definition
Zarbock A, Kellum JA, Schmidt C, et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA. 016 May 24-31;315(20):2190-9.
Gaudry S, Hajage D, Schortgen F, et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med. 2016 Jul 14;375(2):122-33.
Barbar SD, Clere-Jehl R, Bourredjem A, IDEAL-ICU Trial Investigators and the CRICS TRIGGERSEP Network. Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis. N Engl J Med. 2018 Oct 11;379(15):1431-1442.
Pathophysiology of AKI in ACVD patients
Singh S, Kanwar A, Sundaragiri PR, et al. Acute Kidney Injury in Cardiogenic Shock: An Updated Narrative Review. J Cardiovasc Dev Dis. 2021 Jul 28;8(8):88.
Zarbock A, Kellum JA, Schmidt C, et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA.
Gaudry S, Hajage D, Schortgen F, et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med. 2016 Jul 14;375(2):122-33.
Barbar SD, Clere-Jehl R, Bourredjem A, IDEAL-ICU Trial Investigators and the CRICS TRIGGERSEP Network. Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis. N Engl J Med. 2018 Oct 11;379(15):1431-1442.
When to initiate early RRT?
Severe hyperkalemia
Uremia and its complications (encephalopathy, pericarditis, etc.)
Severe metabolic acidosis
Intoxication with dialysable toxins
Significant fluid overload
Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet. 2018 Jul 7;392(10141):31-40.
Zarbock A, Kellum JA, Schmidt C, Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA. 2016 May 24-31;315(20):2190-9.
What are possible advantages of early RRT?
1. Hemodynamic Stability & Fluid Balance
Reduction of Venous Congestion
• AKI + volume overload → ↑ right atrial/venous pressures → myocardial stress, ↓ oxygen delivery
• CRRT → controlled fluid removal → ↓ congestion without hypotension
Interruption of Cardiorenal Syndrome
• Type 1 CRS → heart failure → AKI → fluid overload → worsening cardiac & renal function
• CRRT → breaks cycle → prevents further decline
2. Metabolic Stabilization
Correction of Electrolyte Imbalances
• Hyperkalemia → risk of malignant arrhythmias
• Other electrolytes (Na, P, Ca)→ Stabilizes cardiac & cellular function
Management of Metabolic Acidemia
• Acidemia → ↓ myocardial contractility, vasodilation, catecholamine resistance/insensitivity
Toxin Clearance
• Uremic toxins → cardiac dysfunction, immune suppression, coagulopathy
What are possible advantages of early RRT?
3. Inflammatory & Neurohormonal Modulation
Cytokine & Inflammatory Mediator Removal
• AKI → systemic inflammation → vasomotor dysfunction, myocardial depression
Neurohormonal Regulation
• RAAS & Sympathetic Activation → vasoconstriction, Na retention, K shifts
4. Prevention of multiorgan dysfunction
� Pulmonary Consequences
• Fluid overload → ↑ pulmonary capillary wedge pressure → pulmonary edema, hypoxia
Hepatic & Splanchnic Congestion
• Venous congestion → hepatic congestion leading to impaired function, coagulopathy, intestinal edema
Cerebral Edema & Neurological Impact
• Fluid overload + metabolic derangements → ↑ ICP, encephalopathy
Landmark trials
AKIKI trial
NEJM, 2016
� 💡 Message: Many ICU patients recover kidney function without dialysis, avoiding unnecessary intervention
STARRT-AKI trial
💡 Message: No survival benefit, but higher long-term risks
NEJM, 2020
IDEAL-ICU trial
. No mortality difference
. caveat: Only septic shock patients
. stopped early due to futility
NEJM, 2018
Delayed strategy (KDIGO 3 with oliguria >72 hours or urea 40-50 mmol/L) or more delayed strategy (urea >50 mmol/l or hyperkalemia, acidosis, pulmonary edema)
AKIKI 2 TRIAL
Lancet, 2021
Zarbock A, Kellum JA, Schmidt C, Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA. 2016 May 24-31;315(20):2190-9.
Early RRT (≤8h after KDIGO stage 2) vs. Delayed RRT (< 12 hours of progression to KDIGO 3, or in urgent indications).
90-Day Mortality:�Early: 39.3%. Delayed: 54.7%. HR: 0.66 (P = .03). Absolute reduction: -15.4%.
Renal Recovery by Day 90:�Early: 53.6%. Delayed: 38.7%. OR: 0.55 (P = .02). Improvement: +14.9%.
Duration of RRT:�Early: Median 9 days. Delayed: Median 25 days. HR: 0.69 (P = .04).
Hospital Stay:�Early: Median 51 days. Delayed: Median 82 days. HR: 0.34 (P < .001). Reduction: -37 days.
ELAIN Trial weaknesses
But…
Chen JJ, Lee CC, Kuo G, et al. Comparison between watchful waiting strategy and early initiation of renal replacement therapy in the critically ill acute kidney injury population: an updated systematic review and meta-analysis. Ann Intensive Care. 2020 Mar 3;10(1):30.
NGAL
Early Biomarker for AKI:
Mechanism of Action:
NGAL Sources:
Clinical Utility:
Limitations:
Romejko K, Markowska M, Niemczyk S. The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL). Int J Mol Sci. 2023 Jun 21;24(13):10470.
Xu C, Lin S, Mao L, Li Z. Neutrophil gelatinase-associated lipocalin as predictor of acute kidney injury requiring renal replacement therapy: A systematic review and meta-analysis. Front Med (Lausanne). 2022 Sep 21;9:859318.
Furosemide stress test
Furosemide Stress Test (FST)
Procedure:
• 1 mg/kg IV furosemide (1.5 mg/kg if loop diuretics were used in the prior 7 days) + fluid resuscitation
Criteria:
• FST-responsive: Urine output > 200 mL in 2 hours
• FST-nonresponsive: Urine output ≤ 200 mL in 2 hours
Results
• FST non-responders were 2.7x more likely to initiate CRRT (P=0,0001)
Zhang K, Zhang H, Zhao C, et al. The furosemide stress test predicts the timing of continuous renal replacement therapy initiation in critically ill patients with acute kidney injury: a double-blind prospective intervention cohort study. Eur J Med Res. 2023 Apr 5;28(1):149.
Catheters in critically ill
Calviño Günther, Int. Care Med, 2016
Hypotension
Dialysis therapy in ICU
💰 Mean daily cost of CVVHDF is ± $2,143.
Key Messages
Thank you for your time!